Brief: JW (Cayman) Therapeutics H1 Net Income RMB -267.3 Million
27/08/2025 12:49
Aug 27 (Reuters) - JW (Cayman) Therapeutics Co Ltd 2126.HK: H1 GROSS MARGIN OF SALES OF PRODUCTS 51.1% H1 REVENUE RMB 106.3 MILLION H1 NET INCOME RMB -267.3 MILLION H1 GROSS PROFIT RMB 65.1 MILLION Further company coverage: 2126.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on JW (Cayman) Therapeutics Co
See all newsChina pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says
Brief: JW (Cayman) Therapeutics Appoints Tian Feng As CEO, Executive Director
Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment
Brief: JW (Cayman) Therapeutics H1 Net Income RMB -267.3 Million
Brief: JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License